Medical Devices US

US Multi-Cancer Early Detection Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

US Multi-Cancer Early Detection Market Industry Trends and Forecast to 2034: Segmented by (Technology, Setting, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

US · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $532.3 Mn Placeholder estimate
Estimate 2025 $655.9 Mn 35% of the global market
Projected 2034 $4.29 Bn 553.9% Adds $3.63 Bn over 9 forecast years
CAGR 2025–2034 23.2% Faster than 98% of 173 Medical Devices markets here
Key players 5
  • US is 34.98% of the global market.
  • In North America, the largest is US (this report) at $655.9 Mn.
  • Fastest growing: Canada at 24.9% a year.
  • US ranks 1st of 2 by size in North America.

Market size projection

US

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$3.63 Bn total, 2026–2034

Year-by-year market size, 2024–2034
Multi-Cancer Early Detection Market market size by year, US
YearMarket sizeChange that yearSince 2025
2024 (estimate) $532.3 Mn — —
2025 (base) $655.9 Mn +$123.5 Mn —
2026 (forecast) $808.0 Mn +$152.2 Mn +23.2%
2027 (forecast) $995.5 Mn +$187.5 Mn +51.8%
2028 (forecast) $1.23 Bn +$230.9 Mn +87%
2029 (forecast) $1.51 Bn +$284.5 Mn +130.4%
2030 (forecast) $1.86 Bn +$350.5 Mn +183.8%
2031 (forecast) $2.29 Bn +$431.9 Mn +249.7%
2032 (forecast) $2.83 Bn +$532.1 Mn +330.8%
2033 (forecast) $3.48 Bn +$655.5 Mn +430.7%
2034 (forecast) $4.29 Bn +$807.6 Mn +553.9%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

US Multi-Cancer Early Detection Market Analysis at a glance
Market size, 2025$655.9 Mn placeholder estimate
Forecast, 2034$4.29 Bn placeholder estimate
Growth (CAGR), 2025–203423.2% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsTechnology, setting and end user (see all)
Key playersGRAIL, Exact Sciences Corporation, Guardant Health, Inc., Freenome, Delfi Diagnostics (see all)
Regulator in the USFDASource: US Food and Drug Administration. Checked 14 Nov 2026.
Active clinical trials24 in the USSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in the US. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The US Multi-Cancer Early Detection Market Analysis Executive Summary

Multi-cancer early detection tests look for signs of many cancer types in one blood draw, before symptoms appear.

Key segments of the multi-Cancer Early Detection market include technology (Methylation Analysis, Fragmentomics and Protein Biomarkers) and setting (Primary Care, Employer Programs and Direct-to-Consumer).

Bar chart: US Multi-Cancer Early Detection market size, 2024–2034, placeholder estimates. $532.3 Mn in 2024, $655.9 Mn in 2025 and $4.29 Bn in 2034, 23.2% CAGR.
US Multi-Cancer Early Detection market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

US Multi-Cancer Early Detection Market Dynamics

Market Growth Drivers

Rising cancer cases, earlier detection, precision medicine and a strong pipeline of targeted and immune therapies are driving the multi-Cancer Early Detection market. Faster approvals and new combinations are improving survival.

Opportunity

Biomarker-led treatment, earlier lines of therapy and expansion into emerging markets offer strong growth for the multi-Cancer Early Detection market.

Market Restraints

High treatment costs, drug resistance, side effects and unequal access to cancer centres hold back the multi-Cancer Early Detection market, especially in low- and middle-income countries.

Competitive Landscape for Multi-Cancer Early Detection Market in US

The multi-Cancer Early Detection market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Multi-Cancer Early Detection Market in US

Multi-Cancer Early Detection in the US: rules, payment and research

The FDA clears or approves medical devices by risk class, through 510(k) clearance, De Novo classification or premarket approval (PMA).⁠[1] Medicare covers people aged 65 and over and some younger people with disabilities, and Medicaid covers many people on low incomes; both are run with the Centers for Medicare & Medicaid Services (CMS).⁠[2] ClinicalTrials.gov lists 24 studies on Multi-Cancer Early Detection that are recruiting, active or about to start in the US.⁠[3]

[1] US Food and Drug Administration. Checked 14 Nov 2026.

[2] Centers for Medicare & Medicaid Services. Checked 14 Nov 2026.

[3] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in the US. Retrieved 12 Nov 2026.

Policy changes and Reimbursement scenario

Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how multi-Cancer Early Detection products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in US.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Multi-Cancer Early Detection right now, from free public sources.

Clinical trials

24 active trials in the US

Recruiting, about to start, or running now.

Top trial sponsors (worldwide)

  1. GRAIL 3 active trials on ClinicalTrials.gov (opens in a new tab)

Source: ClinicalTrials.gov, Industry lead sponsors of active studies found with this market's trial search, worldwide. Retrieved 13 Nov 2026.

See every trial on ClinicalTrials.gov (opens in a new tab)

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Multi-Cancer Early Detection in context

The US compared

  • Health spending per person: 13,473 US$ per person (2023). World: 1,317 US$ per person (2023).[1]
  • Doctors: 3.68 per 1,000 people (2022). World: 1.86 per 1,000 people (2022).[2]
  • People aged 65 and over: 18.4% of people (2025). World: 10.4% of people (2025).[3]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 16 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 16 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 16 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the Multi-Cancer Early Detection market in the US?
Placeholder estimate: about $655.9 Mn in 2025, rising to about $4.29 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Multi-Cancer Early Detection market in the US growing?
Placeholder estimate: about 23.2% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Multi-Cancer Early Detection market report cover?
The report splits the market by technology (Methylation Analysis, Fragmentomics, Protein Biomarkers), setting (Primary Care, Employer Programs, Direct-to-Consumer) and end user (Hospitals, Ambulatory Surgical Centers, Diagnostic Centers, Home Care Settings).
Who are the key players in the Multi-Cancer Early Detection market?
Key players include GRAIL, Exact Sciences Corporation, Guardant Health, Inc., Freenome and Delfi Diagnostics.
What is driving the Multi-Cancer Early Detection market?
Rising cancer cases, earlier detection, precision medicine and a strong pipeline of targeted and immune therapies are driving the multi-Cancer Early Detection market. Faster approvals and new combinations are improving survival.
Who regulates Multi-Cancer Early Detection in the US?
The FDA clears or approves medical devices by risk class, through 510(k) clearance, De Novo classification or premarket approval (PMA). Source: US Food and Drug Administration. Checked 14 Nov 2026.
How is healthcare paid for in the US?
Medicare covers people aged 65 and over and some younger people with disabilities, and Medicaid covers many people on low incomes; both are run with the Centers for Medicare & Medicaid Services (CMS). Source: Centers for Medicare & Medicaid Services. Checked 14 Nov 2026.
How many clinical trials on Multi-Cancer Early Detection are running in the US?
24 studies are recruiting, active or about to start in the US, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in the US. Retrieved 12 Nov 2026.
How much research is published on Multi-Cancer Early Detection?
PubMed lists 234 papers on Multi-Cancer Early Detection added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Medical Devices reports in US

See all

Related on oncology and diagnostics and lab testing

See the topic